ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2251

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study

Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Koji Kato6, Arathi Setty6, Tianming Gao6, Diane Caballero7, Ralph Lippe8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie, Inc., Chicago, IL, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 9University of California San Diego, School of Medicine, Riverside, CA

Meeting: ACR Convergence 2023

Keywords: Anti-TNF Drugs, Biologicals, Inflammation, pain, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via reduction of inflammation and potentially by other means, such as a direct analgesic drug effect. The objective of this analysis of the SELECT-PsA 1 study was to assess the direct and indirect (ie, by changes in inflammation surrogates) effects of treatment with upadacitinib (UPA), a selective and reversible Janus kinase (JAK) inhibitor, or adalimumab (ADA), a TNF inhibitor, vs placebo (PBO) on pain in patients with PsA.

Methods: SELECT-PsA 1 was a randomized, double-blind phase 3 study in patients with PsA who had active disease at baseline. Adults (≥18 years) were randomized 1:1:1:1 to UPA 15 mg once daily, UPA 30 mg once daily, ADA 40 mg every other week, or PBO; for UPA, only UPA 15 mg data are reported here. As observed analysis was used for change from baseline to week 16 in Patient’s Global Assessment (PtGA) of pain (1–100 mm) or tender joint count based on 28 joints (TJC28). Observed case multiple mediation analysis1 for effect of UPA vs PBO and ADA vs PBO on pain (pain assessed as PtGA of pain or TJC28) was conducted. Indirect effect of treatment on pain was assessed based on inflammatory factors including itch, total enthesitis, Leeds Enthesitis Index (LEI), and CRP.

Results: 1281 patients were included in this analysis (UPA, n=429, ADA, n=429, PBO, n=423).PtGA of pain significantly improved with UPA vs PBO from baseline to week 16 (–25.0 [n=404] vs –11.0 [n=390]; P< 0.05; Figure 1). Improvements in pain were also observed with ADA at week 16 (–23.0 [n=408]). Total effects (15.1 and 12.4) and direct effects (9.8 and 8.3) on improvement in PtGA of pain were significantly greater with both UPA vs PBO and ADA vs PBO, respectively at week 16 (all P< 0.001; Figure 2); numerically greater reductions in total effect on pain were observed with UPA vs ADA. Direct and indirect effects on pain assessed as improvement in PtGA of pain were numerically greater with UPA vs ADA (Figure 2). Improvement in elicited pain assessed asTJC28 was also significantly greater with UPA and ADA vs PBO (all P< 0.05; Figure 3). Furthermore, UPA reduced pain assessed as TJC28 numerically more than ADA when examining the total effect explained by direct effects and the inflammatory mediators (indirect effects).

Conclusion: UPA and ADA produced relevantly higher mean improvements in pain via inflammatory or non-inflammatory mechanisms vs PBO in patients with PsA. Total effects on pain improvement were numerically greater with UPA vs ADA when assessed as PtGA of pain and TJC28.

Reference: 1Preacher, KJ & Hayes, AF. Behavior Research Methods,2008;40(3), 879–891.

Supporting image 1

Figure 1. Change from Baseline in PtGA of Pain (mm) at Week 16

Supporting image 2

Figure 2. Direct and Indirect Effects of Treatment on Pain Assessed as Improvement in PtGA of Pain at Week 16

Supporting image 3

Figure 3. Direct and Indirect Effects of Treatment on Pain Assessed as Improvement in TJC28 at Week 16


Disclosures: P. Taylor: AbbVie, 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 5, Gilead Sciences, 2, GSK, 2, Janssen, 2, Nordic Pharma, 2, Pfizer Inc, 2, Sanofi, 2, UCB, 2; D. Walsh: AbbVie, 2, Contura International A/S, 2, Eli Lilly, 5, GlaxoSmithKline Research & Development Limited, 5, Orion Corporation, 5, Pfizer, 5; T. Takeuchi: AbbVie, 2, 5, 6, AYUMI, 5, Bristol-Myers Squibb, 6, Chugai, 2, 5, 6, Daiichi Sankyo, 5, Eisai, 5, 6, Eli Lilly Japan, 2, 6, Gilead, 2, 6, Janssen, 6, Mitsubishi-Tanabe, 2, 5, 6, ONO, 5, Pfizer Japan, 6, Taiho, 2; B. Fautrel: AbbVie, 2, BMS, 2, Chugai, 2, Fresenius Kabi, 2, Galapagos, 2, Lilly, 2, Medac, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Sobi, 2, UCB, 2; J. Pope: AbbVie, 1, 2; K. Kato: AbbVie/Abbott, 3, 11; A. Setty: AbbVie, 3, 11; T. Gao: AbbVie, 3, 11; D. Caballero: AbbVie, 3, 11; R. Lippe: AbbVie, 3, 11; A. Kavanaugh: AbbVie, 1, 2, Amgen, 1, 2, BMS, 1, 2, Eli Lilly, 1, 2, Novartis, 1, 2, Pfizer, 1, 2, UCB, 1, 2.

To cite this abstract in AMA style:

Taylor P, Walsh D, Takeuchi T, Fautrel B, Pope J, Kato K, Setty A, Gao T, Caballero D, Lippe R, Kavanaugh A. Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/direct-and-indirect-effects-of-upadacitinib-or-adalimumab-on-pain-in-psoriatic-arthritis-results-from-a-randomized-phase-3-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/direct-and-indirect-effects-of-upadacitinib-or-adalimumab-on-pain-in-psoriatic-arthritis-results-from-a-randomized-phase-3-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology